CC4-03: The Use of Administrative Data and Natural Language Processing to Estimate the Incidence of Statin-related Rhabdomyolysis

Abstract

References: 1. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346(7):539-540. 2. Andrade SE, Graham DJ, Staffa JA, et al. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. J Clin Epidemiol. 2005;58(2):171-174. 3. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-2590. 4. Armitage J, Bowman L, Wallendszus K, et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658-1669. 5. Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med. 2011;365(4):285-287.